ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1193

EMR-integrated Disease Activity Calculators Improve Treatment to Target in Rheumatoid Arthritis

Gabrielle Barbera1, Jasleen Kahlon 2, Manank Patel 3, Scott Pompa 4 and Arundathi Jayatilleke 1, 1Drexel, Philadelphia, PA, 2Hahnemann, Philadelphia, PA, 3Rutgers, New Brunswick, NJ, 4Dartmouth, Lebanon, NH

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Disease Activity, Electronic Health Record, rheumatoid arthritis (RA) and rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Measures Of Healthcare Quality Poster II: Improving Care

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Undertreatment of RA can lead to cumulative joint damage as well as negatively impact emotional health. Recent evidence favors a treat-to-target strategy to achieve remission or low disease activity (DA) using objective scores such as the clinical disease activity index (CDAI) or the DAS28. We hypothesized that integration of CDAI and DAS28 calculators into electronic medical records (EMR) would improve treatment to target.

Methods: We performed a retrospective chart review of all RA patients in our academic rheumatology clinic who had a documented DA score, comparing treatment practices for 18 months before and after calculator implementation (March 2015). We identified patients using ICD-9 and ICD-10 codes for RA. Before implementation, we used natural language processing to search note text for CDAI, DAS, DAS28, DAS 28,  and “disease activity score.” After implementation, we searched for results of DAS28-ESR, DAS28-CRP, and CDAI calculators in patient charts. We analyzed charts for a step-up/switch (addition or increase in dose of steroid or addition, dose increase, or change of synthetic or biologic DMARD), no change, or step down in therapy in response to the first moderate or high score for each patient.

Results: Prior to incorporation of DA calculators in the EMR, out of 732 patients, 14% had at least one recorded CDAI and 4% had at least one DAS28, respectively. After implementation, out of 895 patients, 23% , 2.6%, and 17% had at least one recorded CDAI, DAS28-CRP, and DAS28-ESR, respectively. Both before and after calculator implementation, therapy was intensified the majority of the time in patients with moderate (50-60%) or high activity (80-100%) (see figures 1 and 2).

Conclusion: As expected, implementation of EMR-integrated DA calculators greatly improved DA score documentation. However, even after calculator integration in our EMR, scores were recorded < 25% of the time, with CDAI being the most commonly used measure. For patients in whom DA calculators are used, providers in our clinic adjusted therapy in response to DA level about 50-60% of the time after a moderate DAS and about 90% of the time after a high DA score, suggesting that they are following the treat-to-target recommendations. Targeted education to increase provider use of existing DA calculators may thus lead to improved patient outcomes. We plan to systematically examine charts to understand why there was no change or a step down in therapy in patients with moderate or high DA. Future studies include examining the time to initiation of biologic therapy in newly diagnosed RA patients before and after implementation of EMR DA calculators to assess impact on prescribing practices.


Figure 1

modification of RA treatment to target prior to implementation of EMR DAS calculators


Figure 2

modification of RA treatment to target after implementation of EMR-based CDAI and DAS28 calculators


Disclosure: G. Barbera, None; J. Kahlon, None; M. Patel, None; S. Pompa, None; A. Jayatilleke, None.

To cite this abstract in AMA style:

Barbera G, Kahlon J, Patel M, Pompa S, Jayatilleke A. EMR-integrated Disease Activity Calculators Improve Treatment to Target in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/emr-integrated-disease-activity-calculators-improve-treatment-to-target-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/emr-integrated-disease-activity-calculators-improve-treatment-to-target-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology